press-center
Biopharma has completed clinical trials of immunoglobulin (Bioven) in the complex therapy of patients with pneumonia caused by coronavirus infection COVID-19
An open multicenter randomized controlled trial was conducted at 9 clinical bases:
To learn more
First Patient Enrolled in NIH Phase 3 Trial to Evaluate Potential COVID-19 Hyperimmune Medicine
The Alliance’s anti-COVID-19 Hyperimmune Globulin (CoVIg-19) medicine is under evaluation as part of the trial and may become one of the earliest treatments for hospitalized individuals at risk for serious complications of COVID-19
To learn more
“In the fight against coronavirus, Ukraine focuses its efforts on the “Bioven” production”.
Minister of Healthcare of Ukraine Maksym Stepanov.
To learn more
Chairman of the Parliament of Ukraine, Dmytro Razumkov, visited the Biopharma Blood Center in Sumy.
Sumy is the capital of blood donation in Ukraine, - Dmytro Razumkov.
To learn more
ClinicalTrials.gov has published clinical trials of Bioven.
The study is about Efficacy of Bioven in the High Immunomodulatory Dose in Complex Treatment of Severe Pneumonia Caused by COVID-19 / SARS-CoV-2.
To learn more
Biopharma leased and renovated an old blood transfusion station in Cherkasy.
Ukrainian singer Oleh Vynnyk became one of the first donors.
To learn more
BIOPHARMA HELPS TO FIGHT COVID 19
PHARMACEUTICAL COMPANY SENDS UAH12 MLN TO BUY EQUIPMENT FOR PUBLIC HEALTH CENTERS
To learn more
Biopharma is joining the Global Collaboration to accelerate development of potential COVID-19 Hyperimmune Therapy
The world's leaders in the production of plasma-derived drugs have joined forces to accelerate the development and production of hyperimmune immunoglobulin.
To learn more
Biopharma will support the program of endoprosthetics for adult patients with hemophilia (ukr)
"Our goal is to enable Ukrainian adult patients with hemophilia to lead a healthy life", - the president of the group of companies Biopharma K. Efimenko
To learn more